Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors-Reference-Cited by-同舟云学术

Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors

Published:2022-02-03 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Alkabbani Wajd¹^ORCID,Gamble John‐Michael¹^ORCID

Affiliation:

1. School of Pharmacy University of Waterloo Kitchener ON Canada

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15178

Reference53 articles.

1. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

2. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review;Dias P;Curr Drug Saf,2015

3. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations

4. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?

5. Good Signal Detection Practices: Evidence from IMI PROTECT

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving role of disproportionality analysis in pharmacovigilance;Expert Opinion on Drug Safety;2024-06-24

2. Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database;Drug Safety;2024-05-09

3. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis;Drug Safety;2024-05-04

4. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System;Targeted Oncology;2024-05

5. Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database;Frontiers in Pharmacology;2024-03-20